168 related articles for article (PubMed ID: 30573767)
1. Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo.
Khan I; Spencer-Smith R; O'Bryan JP
Oncogene; 2019 Apr; 38(16):2984-2993. PubMed ID: 30573767
[TBL] [Abstract][Full Text] [Related]
2. Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.
Spencer-Smith R; Li L; Prasad S; Koide A; Koide S; O'Bryan JP
Small GTPases; 2019 Sep; 10(5):378-387. PubMed ID: 28692342
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the α4-α5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association.
Whaby M; Wallon L; Mazzei M; Khan I; Teng KW; Koide S; O'Bryan JP
J Biol Chem; 2022 Dec; 298(12):102661. PubMed ID: 36334633
[TBL] [Abstract][Full Text] [Related]
4. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.
Khan I; Marelia-Bennet C; Lefler J; Zuberi M; Denbaum E; Koide A; Connor DM; Broome AM; Pécot T; Timmers C; Ostrowski MC; Koide S; O'Bryan JP
Small GTPases; 2022 Jan; 13(1):114-127. PubMed ID: 33949915
[No Abstract] [Full Text] [Related]
5. Inhibition of RAS function through targeting an allosteric regulatory site.
Spencer-Smith R; Koide A; Zhou Y; Eguchi RR; Sha F; Gajwani P; Santana D; Gupta A; Jacobs M; Herrero-Garcia E; Cobbert J; Lavoie H; Smith M; Rajakulendran T; Dowdell E; Okur MN; Dementieva I; Sicheri F; Therrien M; Hancock JF; Ikura M; Koide S; O'Bryan JP
Nat Chem Biol; 2017 Jan; 13(1):62-68. PubMed ID: 27820802
[TBL] [Abstract][Full Text] [Related]
6. Correction: Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo.
Khan I; Spencer-Smith R; O'Bryan JP
Oncogene; 2019 May; 38(22):4426. PubMed ID: 30710144
[TBL] [Abstract][Full Text] [Related]
7. K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity.
Samuel MS; Lourenço FC; Olson MF
PLoS One; 2011 Feb; 6(2):e17143. PubMed ID: 21358804
[TBL] [Abstract][Full Text] [Related]
8. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.
Van Sciver RE; Lee MP; Lee CD; Lafever AC; Svyatova E; Kanda K; Colliver AL; Siewertsz van Reesema LL; Tang-Tan AM; Zheleva V; Bwayi MN; Bian M; Schmidt RL; Matrisian LM; Petersen GM; Tang AH
Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29757973
[TBL] [Abstract][Full Text] [Related]
9. Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Triggered by R135K Mutation.
Ni D; Song K; Zhang J; Lu S
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29072601
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
11. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
Shi XH; Liang ZY; Ren XY; Liu TH
Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011
[TBL] [Abstract][Full Text] [Related]
12. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
[TBL] [Abstract][Full Text] [Related]
13. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
14. Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity.
Henkels KM; Rehl KM; Cho KJ
Front Mol Biosci; 2021; 8():673096. PubMed ID: 34222333
[TBL] [Abstract][Full Text] [Related]
15. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
[TBL] [Abstract][Full Text] [Related]
17. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
18. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue.
Schmidt RL; Park CH; Ahmed AU; Gundelach JH; Reed NR; Cheng S; Knudsen BE; Tang AH
Cancer Res; 2007 Dec; 67(24):11798-810. PubMed ID: 18089810
[TBL] [Abstract][Full Text] [Related]
20. Selective killing of K-ras-transformed pancreatic cancer cells by targeting NAD(P)H oxidase.
Wang P; Sun YC; Lu WH; Huang P; Hu Y
Chin J Cancer; 2015 Apr; 34(4):166-76. PubMed ID: 25963558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
